Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Frequently asked questions
What sector does SCNX (SCNX) operate in?
SCNX belongs to the Healthcare sector and operates in the Pharmaceutical Retailers industry.
What is SCNX (SCNX) current stock price?
As of the latest data, SCNX stock price is $0.46, with a previous close of $0.47. SCNX lost -$0.01 in the last trading session, representing a -2.62% loss.
What is SCNX (SCNX) current market capitalization?
SCNX market cap is approximately 18.56 million.
What is SCNX (SCNX) Earnings Per Share (EPS)?
The trailing EPS is -$2.60, and the forward EPS is -$0.06.
What is SCNX (SCNX) EBITDA?
SCNX EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.90 million.
Does SCNX (SCNX) pay dividends?
No. SCNX does not pay a dividend.
What is SCNX (SCNX) beta (volatility) score?
SCNX has a beta of 3.958, indicating very high volatility compared to the market.
